Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Down 48.9% in May

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 225,674 shares, a drop of 48.9% from the May 14th total of 441,245 shares. Currently, 4.4% of the company’s shares are sold short. Based on an average daily volume of 279,716 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Ikarian Capital LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at about $124,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at about $37,000. Finally, Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at about $26,000. Institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Price Performance

Shares of NASDAQ SHPH opened at $3.91 on Friday. The company has a market cap of $2.50 million, a P/E ratio of -0.82 and a beta of 0.18. Shuttle Pharmaceuticals has a 1 year low of $3.57 and a 1 year high of $55.90. The firm has a 50-day simple moving average of $7.12 and a two-hundred day simple moving average of $11.87.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .